Cargando…

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms

Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden and tumour-infiltrating lymphocytes. Studies have shown a sustained clinical response to immune che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahin, Ibrahim Halil, Akce, Mehmet, Alese, Olatunji, Shaib, Walid, Lesinski, Gregory B., El-Rayes, Bassel, Wu, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889302/ https://www.ncbi.nlm.nih.gov/pubmed/31607751 http://dx.doi.org/10.1038/s41416-019-0599-y

Ejemplares similares

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival
por: Alese, Olatunji B., et al.
Publicado: (2021)

Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
por: Akce, Mehmet, et al.
Publicado: (2023)

Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status
por: Akce, Mehmet, et al.
Publicado: (2021)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma
por: Zakka, Katerina, et al.
Publicado: (2019)

Blood-based next-generation sequencing analysis of neuroendocrine neoplasms
por: Zakka, Katerina, et al.
Publicado: (2020)

Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study
por: Atallah, Rami P., et al.
Publicado: (2022)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

The Potential of CAR T Cell Therapy in Pancreatic Cancer
por: Akce, Mehmet, et al.
Publicado: (2018)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
por: Nagaraju, Ganji Purnachandra, et al.
Publicado: (2014)

Prediction of biological behavior and prognosis of colorectal cancer patients by tumor MSI/MMR in the Chinese population
por: Yan, Wen-Yue, et al.
Publicado: (2016)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
por: Choi, Jina, et al.
Publicado: (2023)

Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
por: Kang, Sandra, et al.
Publicado: (2022)

Gene Expression Profile Reveals a Prognostic Signature of Non–MSI-H/pMMR Colorectal Cancer
por: Liu, Zaoqu, et al.
Publicado: (2022)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Immune checkpoints in MSI and CSI colorectal cancers and their translational implications
por: Llosa, Nicolás J, et al.
Publicado: (2013)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology
por: Kang, Sandra Mirie, et al.
Publicado: (2022)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
por: Guo, Yu-e, et al.
Publicado: (2022)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
por: Du, YunYi, et al.
Publicado: (2022)

Colorectal Carcinogenesis: MSI-H Versus MSI-L
por: Pawlik, Timothy M., et al.
Publicado: (2004)

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
por: Gallois, Claire, et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gmodi73ko707ilon51rh4hrf8e